Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients
Public ClinicalTrials.gov record NCT00526045. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Dose Escalation, Multi-center, Open-label Study of AUY922 Administered IV on a Once Weekly Schedule in Adult Patients With Advanced Solid Malignancies Including Phase II Expansion Arms in Patients With Either HER2 Positive or ER Positive Locally Advanced or Metastatic Breast Cancer.
Study identification
- NCT ID
- NCT00526045
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 117 participants
Conditions and interventions
Conditions
Interventions
- AUY922 2 mg/m2 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2007
- Primary completion
- Mar 31, 2012
- Completion
- Mar 31, 2012
- Last update posted
- Dec 16, 2020
2007 – 2012
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA/ University of California Los Angeles UCLA | Los Angeles | California | 90095 | — |
| Georgia Health Sciences University Med College of GA | Augusta | Georgia | 30912 | — |
| Dana Farber Cancer Institute StudyCoordinator:CAUY922A2101 | Boston | Massachusetts | 02115 | — |
| Washington University School Of Medicine-Siteman Cancer Ctr Dept. of Siteman Cancer Ctr. | St Louis | Missouri | 63110 | — |
| Nevada Cancer Institute Clinical Trials Office | Las Vegas | Nevada | 89135 | — |
| MD Anderson Cancer Center/University of Texas Thoractic Head/Neck Med.Onc(2) | Houston | Texas | 77030-4009 | — |
| Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(3) | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00526045, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 16, 2020 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00526045 live on ClinicalTrials.gov.